Skip to main content
. 2024 Mar 22;38(5):458–470. doi: 10.1177/02698811241237870

Figure 1.

Figure 1.

BDI (right) and QIDS-SR-16 (left) scores at screening and baseline for those who did and did not discontinue SADs separately. QIDS-SR16 and BDI scores increased from screening to baseline in those who discontinued (Yellow) compared to those who were unmedicated coming into the trial (Green).

*Indicates univariate significance p < 0.05.